Back to Search Start Over

Comparison in toxicity and solubilizing capacity of hydroxypropyl-β-cyclodextrin with different degree of substitution.

Authors :
Li, Pengyu
Song, Jia
Ni, Xiaomin
Guo, Qin
Wen, Hui
Zhou, Qiuyun
Shen, Yuanna
Huang, Yijun
Qiu, Pengxin
Lin, Suizhen
Hu, Haiyan
Source :
International Journal of Pharmaceutics. Nov2016, Vol. 513 Issue 1/2, p347-356. 10p.
Publication Year :
2016

Abstract

Hydroxypropyl-β-cyclodextrin (HP-β-CD) has been widely used as an effective solubilizing agent in pharmaceutical industry for many years. However, the effect of degree of substitution (D.S.) of HP-β-CD on solubilizing capacity and toxicity has not been concerned. In this study, solubilizing capacity of HP-β-CDs with three different D.S. (4.55, 6.16 and 7.76) for 16 drugs were measured and their toxicities were compared by a 7-day i.v. administration ( q.d. ) study in rats. Generally, HP-β-CD with high D.S. (7.76) showed weaker solubilizing capacity for steroids and BCS class II drugs, but lower hemolytic activity, compared with that of HP-β-CD with low (4.55) or medium (6.16) D.S. HP-β-CD with low D.S. resulted in more changes in hematological and biochemical parameters, but the effects were reversible after a 7-day recovery. Moreover, HP-β-CD with medium D.S. may have slightly greater nephrotoxicity than the other two HP-β-CDs. HP-β-CDs with different D.S. had similar urine excretion percentage after i.v. administration and none of them was found to affect glomerular filtration function of rats. The results suggest that HP-β-CD with low D.S. would be a better choice considering both the solubilizing capacity and toxicity. However, comparison in toxicity of HP-β-CDs with different D.S. should be carried out in human in view of its species-dependence property. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
03785173
Volume :
513
Issue :
1/2
Database :
Academic Search Index
Journal :
International Journal of Pharmaceutics
Publication Type :
Academic Journal
Accession number :
119775164
Full Text :
https://doi.org/10.1016/j.ijpharm.2016.09.036